Liver Unit, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, United Kingdom.
Curr Vasc Pharmacol. 2021;19(3):269-279. doi: 10.2174/1570161118666200318103001.
Non-Alcoholic Fatty Liver Disease (NAFLD) represents an increasing cause of liver disease worldwide. However, notably, the primary cause of morbidity and mortality in patients with NAFLD is cardiovascular disease (CVD), with fibrosis stage being the strongest disease-specific predictor. It is globally projected that NAFLD will become increasingly prevalent, especially among children and younger adults. As such, even within the next few years, NAFLD will contribute considerably to the overall CVD burden. In this review, we discuss the role of NAFLD as an emerging risk factor for CVD. In particular, this article aims to provide an overview of pathological drivers of vascular damage in patients with NAFLD. Moreover, the impact of NAFLD on the development, severity and the progression of subclinical and clinical CVD will be discussed. Finally, the review illustrates current and potential future perspectives to screen for CVD in this high-risk population.
非酒精性脂肪性肝病(NAFLD)是全球范围内导致肝脏疾病的主要原因之一。然而,值得注意的是,NAFLD 患者的发病率和死亡率的主要原因是心血管疾病(CVD),纤维化阶段是最强的疾病特异性预测因素。据全球预测,NAFLD 的发病率将会越来越高,尤其是在儿童和年轻成年人中。因此,即使在未来几年内,NAFLD 也将对整体 CVD 负担产生重大影响。在这篇综述中,我们讨论了 NAFLD 作为 CVD 新兴危险因素的作用。本文特别旨在概述 NAFLD 患者血管损伤的病理驱动因素。此外,还将讨论 NAFLD 对亚临床和临床 CVD 的发展、严重程度和进展的影响。最后,本文阐述了在这一高危人群中筛查 CVD 的当前和潜在未来观点。